Goldman Sachs
FTH

Goldman Sachs’s Faeth Therapeutics FTH Stock Holding History

Goldman Sachs’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.94M Buy
+61,568
New +$1.23M ﹤0.01% 4568
2022
Q4 		– Sell
-522
Closed -$16K – 6243
2022
Q3 		$16K Sell
522
-31
-6% -$1.22K ﹤0.01% 5969
2022
Q2 		$25K Sell
553
-81
-13% -$3.04K ﹤0.01% 6142
2022
Q1 		$29K Buy
634
+79
+14% +$6.29K ﹤0.01% 6358
2021
Q4 		$64K Buy
+555
New +$82.9K ﹤0.01% 6222

Other funds holding FTH

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Goldman Sachs's FTH Position: Q1 2026 in Review

Goldman Sachs opened a new position in Faeth Therapeutics (FTH) in Q1 2026: 61,568 shares worth $1.94M. The stake represents ﹤0.01% of the portfolio and ranks #4568 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in FTH as recently as Q3 2022.

Goldman Sachs first reported a position in FTH in Q4 2021 and has held it in 5 quarters since. 30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • Goldman Sachs held 61,568 shares of Faeth Therapeutics worth $1.94M as of Q1 2026.
  • Faeth Therapeutics was a new Goldman Sachs position in Q1 2026.
  • Faeth Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4568 holding.
  • Goldman Sachs first reported a position in Faeth Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.